Hybribio Biotech secures multiple invention patent authorizations

Guangdong Hybribio Biotech (SZSE:300639) announced that it and its subsidiaries secured several invention patent authorizations in April 2025, expanding its intellectual property portfolio. Key patents include a method for separating placental trophoblast cells from cervical exfoliated cells of pregnant women, applicable in prenatal screening and diagnosis, already approved in multiple countries including China, the US and countries in Europe. Additional patents cover primer compositions for detecting Mycobacterium tuberculosis complex and drug resistance genes, and primers used in HPV genotyping assays. These patents support Hybribio's strategic goal of becoming a leader in molecular diagnostics and enriching its product structure. The company believes this will strengthen its core competitiveness.